These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1722795)

  • 1. The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia.
    Lepor H
    J Androl; 1991; 12(6):389-94. PubMed ID: 1722795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha adrenergic antagonists for the treatment of symptomatic BPH.
    Lepor H
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):151-5. PubMed ID: 2469658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
    Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
    Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplasia.
    Shapiro E
    Urol Clin North Am; 1990 Aug; 17(3):487-93. PubMed ID: 1695777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
    Lepor H; Knapp-Maloney G; Wozniak-Petrofsky J
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):392-7. PubMed ID: 2477339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha blockade for the treatment of benign prostatic hyperplasia.
    Lepor H
    Urol Clin North Am; 1995 May; 22(2):375-86. PubMed ID: 7539182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
    Kuritzky L; Rosenberg MT; Sadovsky R
    Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
    Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
    J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Benign hypertrophy of the prostate: which treatment, for whom?].
    Schulman C
    Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia.
    Lepor H
    Urol Clin North Am; 1990 Aug; 17(3):651-9. PubMed ID: 1695785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience: symptomatic management of BPH with terazosin.
    Dunzendorfer U
    Urology; 1988 Dec; 32(6 Suppl):27-31. PubMed ID: 2462302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
    Tsai YS; Lan SK; Ou JH; Tzai TS
    Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current drug therapy of benign prostatic hyperplasia].
    Schmidbauer CP; Madersbacher S
    Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study.
    Dunzendorfer U
    Arzneimittelforschung; 1989 Oct; 39(10):1289-91. PubMed ID: 2482025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
    Plosker GL; Goa KL
    Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.